3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Multiple Myeloma
57
Recurrence
7
Neoplasms, Plasma Cell
5
Neoplasms
4
Smoldering Multiple Myeloma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Paraproteinemias
1
Immunoglobulin Light-chain Amyloidosis
1
Glioblastoma
1
Disease
1
Chromosome 17 deletion
1
Interventions
Temozolomide
41
Radiotherapy
19
Radiation
12
Nivolumab
10
pembrolizumab
8
Magnetic Resonance Spectroscopy
8
Bevacizumab
7
Specimen Handling
6
poly ICLC
4
atezolizumab
4
Lomustine
4
Ipilimumab
4
Surgical Procedures, Operative
3
Photons
3
Immunoglobulin G
3
Disulfides
3
Cyclophosphamide
3
veliparib
2
sargramostim
2
rocakinogene sifuplasmid
2
olaparib
2
niraparib
2
Transurethral Resection of Bladder
2
Surveys and Questionnaires
2
Standard of Care
2
Radiotherapy, Intensity-Modulated
2
Radiosurgery
2
OKN 007
2
Mycophenolic Acid
2
Metformin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Glioblastoma
×
daratumumab
×
Clear all
NCT04922723
2026-04-28
PRIDE
West Virginia University
Phase 1/2
Active not recruiting
16 enrolled